Literature DB >> 20103693

Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.

Melanie S Joy1, Reginald F Frye, Kristi Stubbert, Kim R Brouwer, Ronald J Falk, Evan D Kharasch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20103693      PMCID： PMC3614080          DOI： 10.1177/0091270009353031

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  36 in total

1.  CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.

Authors:  M Hidestrand; M Oscarson; J S Salonen; L Nyman; O Pelkonen; M Turpeinen; M Ingelman-Sundberg
Journal:  Drug Metab Dispos       Date:  2001-11       Impact factor: 3.922

2.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

3.  Cytochrome P4502C9 activity in end-stage renal disease.

Authors:  Albert W Dreisbach; Shanker Japa; Aster B Gebrekal; Sarah E Mowry; Juan J L Lertora; Burde L Kamath; Allan E Rettie
Journal:  Clin Pharmacol Ther       Date:  2003-05       Impact factor: 6.875

4.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

5.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

Authors:  L M Hesse; K Venkatakrishnan; M H Court; L L von Moltke; S X Duan; R I Shader; D J Greenblatt
Journal:  Drug Metab Dispos       Date:  2000-10       Impact factor: 3.922

6.  Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

Authors:  N G Grubb; D W Rudy; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

7.  Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators.

Authors:  Carl Guévin; Josée Michaud; Judith Naud; Francois A Leblond; Vincent Pichette
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

8.  Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease.

Authors:  Thomas C Dowling; Andrew E Briglia; Jeffrey C Fink; Donna S Hanes; Paul D Light; Lucy Stackiewicz; Chetan S Karyekar; Natalie D Eddington; Matthew R Weir; William L Henrich
Journal:  Clin Pharmacol Ther       Date:  2003-05       Impact factor: 6.875

9.  Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.

Authors:  Rebecka Coles; Evan D Kharasch
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

10.  Pharmacokinetics of mycophenolic acid in patients with lupus nephritis.

Authors:  Melanie S Joy; Tandrea Hilliard; Yichun Hu; Susan L Hogan; Mary Anne Dooley; Ronald J Falk; Philip C Smith
Journal:  Pharmacotherapy       Date:  2009-01       Impact factor: 4.705
View more
  4 in total

Review 1.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

2.  Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.

Authors:  Aaron M Teitelbaum; Alicia M Flaker; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-27       Impact factor: 3.205

3.  In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.

Authors:  Melanie S Joy; Reginald F Frye; Thomas D Nolin; Brittney V Roberts; Mary K La; Jinzhao Wang; Kim L R Brouwer; Mary Anne Dooley; Ronald J Falk
Journal:  Pharmacotherapy       Date:  2013-09-06       Impact factor: 4.705

4.  The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.

Authors:  Andrew S Kucey; Thomas J Velenosi; Nicholas C Tonial; Alvin Tieu; Adrien A E RaoPeters; Brad L Urquhart
Journal:  Pharmacol Res Perspect       Date:  2019-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.